Last updated on December 2018

Evaluating Immune Therapy Durvalumab (MEDI4736) With Tremelimumab for Metastatic Non-transitional Cell Carcinoma of the Urinary Tract


Brief description of study

This study is being done test to test the safety and effectiveness of durvalumab combined with tremelimumab in patients who have a rare form of cancer of the urinary tract.

Clinical Study Identifier: NCT03430895

Find a site near you

Start Over

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.